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Nuclear poly(ADP-ribose) activity is a
therapeutic target in amyotrophic lateral
sclerosis
L. McGurk1, J. Mojsilovic-Petrovic2,3, V. M. Van Deerlin4, J. Shorter5, R. G. Kalb2,3, V. M. Lee4, J. Q. Trojanowski4,
E. B. Lee4,6 and N. M. Bonini1*
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal motor neuron disease. Diagnosis typically occurs in the
fifth decade of life and the disease progresses rapidly leading to death within ~ 2–5 years of symptomatic onset.
There is no cure, and the few available treatments offer only a modest extension in patient survival. A protein
central to ALS is the nuclear RNA/DNA-binding protein, TDP-43. In > 95% of ALS patients, TDP-43 is cleared from
the nucleus and forms phosphorylated protein aggregates in the cytoplasm of affected neurons and glia. We
recently defined that poly(ADP-ribose) (PAR) activity regulates TDP-43-associated toxicity. PAR is a posttranslational
modification that is attached to target proteins by PAR polymerases (PARPs). PARP-1 and PARP-2 are the major
enzymes that are active in the nucleus. Here, we uncovered that the motor neurons of the ALS spinal cord
were associated with elevated nuclear PAR, suggesting elevated PARP activity. Veliparib, a small-molecule
inhibitor of nuclear PARP-1/2, mitigated the formation of cytoplasmic TDP-43 aggregates in mammalian cells. In
primary spinal-cord cultures from rat, Veliparib also inhibited TDP-43-associated neuronal death. These studies uncover
that PAR activity is misregulated in the ALS spinal cord, and a small-molecular inhibitor of PARP-1/2 activity may have
therapeutic potential in the treatment of ALS and related disorders associated with abnormal TDP-43 homeostasis.
Keywords: ABT-888/Veliparib, Parp, Poly(ADP-ribose), PAR, PARylation, Motor neuron disease, primary neuron, TDP-43
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease where the degeneration of upper and
lower motor neurons leads to muscle atrophy, paralysis
and death typically within ~ 2–5 years of disease onset
[47]. In > 95% of ALS patients, the normally nuclear pro-
tein TDP-43 redistributes to the cytoplasm and forms
phosphorylated aggregates in affected neurons and glia
[45, 69, 84, 85]. The treatment options for ALS are
bleak, most are palliative and address the well-being and
comfort of the patient [38, 44, 82, 91]. The first
FDA-approved drug was riluzole, an anti-glutamatergic
that provides a ~ 2–3-month extension in patient sur-
vival [88, 95]. In the 20 years since, a gamut of
treatments has been clinically tested, but most have
failed to demonstrate therapeutic efficacy [9, 38, 88]. In
2017, the second FDA approval was granted to edara-
vone, an anti-oxidant which, when administered with
riluzole, modestly reduces neurological decline in the
early stages of disease [26, 39, 40, 92, 97]. Thus, unco-
vering molecular pathways that contribute to the decline
and loss of motor neurons in ALS is imperative for the
development and testing of new treatments.
Although the exact cause of ALS remains largely un-
known, genetic factors contribute to ~ 5–10% of cases
[65, 107]. Familial genes include SOD1, C9orf72, ATXN2
and TARDBP [28, 29, 89, 90, 104]. Several of the pro-
teins mutated in ALS, including TDP-43 and Ataxin-2,
are components of cytoplasmic stress granules [64],
which are membraneless organelles that are comprised
of translationally-arrested mRNA and associated proteins
[4, 53]. In the ALS spinal cord, several stress-granule
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proteins, such as TIA-1, eIF3, and PABPC-1, co-aggregate
with phosphorylated TDP-43 inclusions [10, 66, 74].
Furthermore, manipulation of proteins that regulate
the stress response is beneficial in animal and cellular
models of ALS [8, 29, 35, 55, 58, 86, 98, 117]. Despite
evidence implicating stress pathways in ALS, it is un-
clear whether they are cause or consequence of the
disease process.
We identified Tankyrase, a poly(ADP-ribose) polymer-
ase, or PARP, as a potent regulator of disease-associated
features of TDP-43 in Drosophila and mammalian cell
models of ALS [73]. PARPs are enzymes that catabolize
NAD+ to sequentially add ADP-ribose subunits onto tar-
get proteins, generating polymers of poly(ADP-ribose)
(PAR) [37]. PAR activity is often stress responsive and
can serve as an upstream signaling molecule [41, 63, 68].
In mammals, the PARP superfamily consists of 17 en-
zymes, with the most abundant and well characterized
being PARP-1 [67, 99]. In the nucleus, PARP-1 and
PARP-2 regulate DNA damage, gene expression, and cell
survival [18, 34, 41, 48, 67]. Here, we report that PAR
levels are elevated in the nuclei of motor neurons in the
spinal cord of ALS patients, and that a PARP-1/2 inhibi-
tor is therapeutic in a rodent spinal-cord cellular
model of TDP-43-associated toxicity. These findings
implicate an alteration in PAR activity in ALS, and
suggest that PARP-1/2 inhibitors, which are in use for
cancer treatment, might be repurposed for
TDP-43-associated disorders.
Materials and methods
Clinical data and patient consent
Patient tissue was obtained from the Center for Neuro-
degenerative Disease Research (CNDR) Brain Bank at
the University of Pennsylvania, brief details are provided
in Tables 1 and 2. Patients were selected on the basis of
having phosphorylated TDP-43 in motor neurons in the
spinal cord. All patients pre-consented for autopsy as
well as at time of death. Consent for autopsy was
re-obtained from the next-of-kin in accordance with in-
stitutional review board guidelines of the University of
Pennsylvania. The University of Pennsylvania Institu-
tional Review Board reviewed and confirmed that the
CNDR Neurodegenerative Disease Autopsy Brain Bank
protocols meet the criteria for human-subjects research.
Immunohistochemistry
Tissue was examined by routine neuropathologic diag-
nostic methods, as described [36, 83, 85, 110]. Briefly,
spinal-cord regions were fixed in 10% neutral buffered
formalin and 6 μm thick sections were cut from
paraffin-embedded tissue. After dewaxing and rehydra-
tion endogenous peroxidases were quenched in 30%
H2O2 made up in methanol (30 min) and washed in run-
ning tap water (10 min). For antibodies requiring antigen
retrieval (only anti-phosphorylated TDP-43) slides were
incubated in a citrate based antigen retrieval (pH 6) buf-
fer (Vector labs #H3300) (15 min at 99 °C) in an
EZ-retriever microwave (BioGenex). Slides and solution
Table 1 Patients with no known neurological disease
# Diagnosis Sex Age at Death (yr) PMI (hr) Brain weight (g) ALS stage Braak stage Thal phase CERAD LBD
1 normal M 47 12 1383 0 I/II 0 0 no
2 normal M 70 10.5 1388 0 I/II 1 0 no
3 normal F 72 7 1406 0 I/II 0 0 no
4 normal F 65 19 1207 0 0 1 0 no
5 normal F 56 12 1416 0 I/II n/a 0 no
6 normal M 61 6 1369 0 0 1 0 no
7 normal M 55 11.5 1448 0 0 n/a 0 no
8 normal F 59 13 1166 0 0 n/a 0 no
9 normal M 68 21 1330 0 I/II 0 0 no
10 normal M 47 11 1333 0 I/II n/a A no
11 normal M 72 13.5 1320 0 I/II 3 A no
12 normal F 46 12 1228 0 0 n/a 0 no
13 normal F 65 22 1206 0 I/II 1 0 no
14 normal M 67 15 1545 0 I/II 2 A no
15 normal F 68 15 1151 0 I/II 0 0 no
16 normal M 70 36 1755 0 0 0 0 no
Abbreviations: #: case number, Normal diagnosed neurologically normal, F female, M male, PMI postmortem interval, ALS stage stages 0–4 semiquantitatively
assessed according to [14, 15]. Braak stage neurofibrillary tangle deposition according to [12, 13]. Thal phase amyloid deposition according to [108]. CERAD neuritic
plaque deposition according to [76, 80]. LBD Lewy Body disease according to [75]. n/a data not available. no no LBD
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were placed in a cool tray and left to cool to room
temperature (~ 20 min). Slides were washed in 0.1 M
Tris pH 7.6 and blocked in 0.1 M Tris pH 7.6 with 2%
FBS. Primary antibodies, in 0.1 M Tris pH 7.6 with 2%
FBS, were applied overnight at 4 °C. Sections were
washed in 0.1 M Tris pH 7.6, blocked in Tris pH 7.6
with 2% FBS, and incubated with biotinylated IgG from
mouse (1 in 1000, Vector labs #BA-2000) or rat (1 in
1000, Vector labs #BA-9401) for 1 h at room
temperature. Slides were washed in 0.1 M Tris pH 7.6
and then 0.1 M Tris pH 7.6 with 2% FBS and incubated
with an avidin-conjugated horseradish peroxidase (Vec-
tastain ABC kit, #PK-6100) made up in Tris pH 7.6 with
2% FBS (1 h at room temperature). Slides were washed
in Tris pH 7.6 and developed with Diaminiobenzidine
(DAB) solution (Vector labs, SK-4105) for 8 min at
room temperature. Slides were counterstained with Har-
ris hematoxylin (30 s), washed in running tap water
(10 min) dehydrated, cleared in xylene and mounted in
cytoseal XYL (ThermoFisher, #8312–4). All Tris based
washes were 5 min. Primary antibodies used were rat
anti-phosphorylated (pS409/410) TDP-43 monoclonal
antibody (1 in 500, [83]) and mouse anti-PAR, BSA free
(1 in 500, Tulip Biolabs, #1020 N). Note, antigen re-
trieval and cooling steps were omitted for anti-PAR la-
belling. The anti-PAR antibody was first optimized by a
serial dilution test (from 1 in 400 to 1 in 25, 000). No
signal was detected at 1 in 25, 000 indicating that the
Table 2 Details of patients diagnosed with ALS-related neurological disease
# Diagnosis Sex Age of
Onset (yr)
Age at
Death (yr)
Disease
Duration (yr)
Mutation
Status
PMI
(hr)
Brain
weight (g)
ALS
Stage
Braak
stage
Thal
phase
CERAD LBD
17 ALS M 41 42 1 – 8 1554 2 I/II n/a 0 no
18 ALS M 71 76 5 – 23 1297 1 I/II n/a A no
19 ALS M 50 53 3 – 24 1422 2 0 n/a 0 no
20 ALS-D F 50 51 1 – 4 1203 4 I/II n/a 0 no
21 ALS M 43 46 3 – 5 1427 3 I/II n/a 0 no
22 ALS F 79 81 2 – 10 1215 4 III/IV n/a 0 no
23 ALS M 64 66 2 – 14 1427 2 I/II n/a 0 no
24 ALS M 76 85 9 – 9 1041 1 V/VI n/a C diffuse
neocortical
25 ALS F 73 75 2 – 8 1405 4 I/II n/a A no
26 ALS-D F 57 59 2 – 18 1125 4 I/II n/a 0 no
27 ALS/PLS M 54 74 20 – 4 1169 1 I/II n/a 0 no
28 ALS M 69 70 1 – 4 1135 1 0 0 0 no
29 ALS F 63 67 4 – 10 1384 2 0 0 0 no
30 ALS F 43 50 7 – n/a 1237 2 0 0 0 no
31 ALS F n/a 48 n/a ATXN2 (22/32) 5 1374 3 0 n/a 0 no
32 ALS-D M n/a 78 n/a ATXN2 (22/27) 6 1300 4 III/IV n/a B transitional
33 ALS F 64 67 3 ATXN2 (20/31) 19 1229 3 I/II n/a 0 no
34 ALS M 63 65 2 ATXN2 (22/29) 7 1395 4 III/IV n/a 0 no
35 ALS F 54 56 2 ATXN2 (22/27) 10 1426 1 I/II n/a 0 no
36 ALS M 52 54 2 C9orf72 4 1536 3 0 n/a 0 no
37 FTD F 47 54 7 C9orf72 12 813 4 III/IV n/a 0 no
38 ALS-D M 55 57 2 C9orf72 9 1200 4 III/IV n/a B no
39 ALS-D M 54 57 3 C9orf72 15 1244 n/a I/II n/a 0 no
40 ALS-D F 67 69 2 C9orf72 21 1079 4 III/IV n/a B no
41 ALS-D M 61 62 1 C9orf72 30 1240 4 I/II n/a 0 no
42 ALS-D M 46 48 2 C9orf72 13 1309 4 I/II n/a 0 no
43 ALS M 70 71 1 C9orf72 18 1221 2 V/VI 2 B no
Abbreviations: #: case number. -: no known mutation in TARDBP, UBQLN2, ATXN2, and C9orf72. ATXN2 refers to an intermediate CAG-trinucleotide expansion
in ATXN2 (pathologic repeat length is indicated in brackets). C9orf72 refers to a GGGGCC-hexanucleotide repeat expansion. ALS-D ALS with dementia, FTD
frontotemporal degeneration, PLS primary lateral sclerosis. F female, M male. PMI postmortem interval. ALS stage stages 0–4 semiquantitatively assessed according to
[14, 15]. Braak stage neurofibrillary tangle deposition according to [12, 13]. Thal phase amyloid deposition according to [108]. CERAD neuritic plaque deposition
according to [76, 80]. LBD Lewy Body disease according to [75]. n/a data not available. no no LBD
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secondary antibody was not contributing to the observed
signal at higher primary concentrations. Dilution tests
were performed on spinal cord tissue from 5 normal
cases and 4 ALS cases.
Slides were coded and blinded and quantified by two
researchers independently. For nuclear PAR scoring, 1–5
sections from every case were quantified and all the
alpha motor neurons present in the anterior horns of
each of section were scored for whether the nucleus was
present and, if so, whether the nucleus stained for PAR.
If all motor neurons with a nucleus were negative for
PAR the score was 0. If 1 or more motor neurons with
nuclei visible in the section were present and stained for
nuclear PAR: a score of + was given if nuclear PAR was
present in 1 motor neuron and ++ if more than 1 motor
neuron stained for nuclear PAR. To determine the num-
ber of alpha motor neurons in ALS and normal spinal
cord, motor neurons from one anterior horn from each
case were counted. In the ALS anterior horn, there were
13.7±1.4 (SEM) alpha motor neurons with 4.0±0.4
(SEM) nuclei exposed. In the normal anterior horn,
there were 19.5±1.4 (SEM) alpha motor neurons with
5.6±0.6 (SEM) nuclei exposed.
Immunofluorescence and cell culture
Human TDP-43-YFP cloned into pcDNA3.2 is described
[29]. Standard cell culture and immunofluorescence tech-
niques were used as described [73]. Briefly, COS-7 cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing high glucose and L-glutamine and
sodium bicarbonate (Sigma-Aldrich, #D5796. 10% fetal
bovine serum (Sigma-Aldrich, #F6178) and 1% penicillin-
streptomycin (ThermoFisher, #15140122) at 37 °C with
5% CO2. For immunofluorescence cells were grown on
glass coverslips coated with poly-L-lysine (NeuVitro,
#H-12-1.5-pll) and transfected with Lipofectamine LTX
and PLUS reagent (ThermoFisher, #15338100) in DMEM
with 10% fetal bovine serum and no antibiotics. The trans-
fection reaction was not removed and experiments were
performed 21 h later. Veliparib (ABT-888, Selleckchem, #
S1004) experiments were performed by supplementing
the media with the inhibitor, cells were pre-treated with
Veliparib or DMSO for 90 min prior to stress. Cells were
then incubated for 30 min with media supplemented with
0.25 mM sodium arsenite and DMSO or Veliparib at the
indicated concentration. Cells were fixed for 15 min in 4%
paraformaldehyde, permeabilized in PEM buffer (100 mM
PIPES, 1 mM MgCl2 and 10 mM EGTA pH 6.8) supple-
mented with 0.1% triton X100 and then blocked in 10%
normal donkey serum (Sigma-Aldrich). The primary anti-
body used was anti-mouse TIAR (1 in 500; BD Biosciences
#5137) and the secondary antibody was Alexa-Fluor-594
(1 in 500; ThermoFisher, # A-21203). Coverslips were
mounted in Prolong Diamond (ThermoFisher, # P36965).
4–5 independent images were captured at 20X magnifica-
tion and the percentage of cells with cytoplasmic
YFP-positive foci or TIAR-labelled stress granules were
quantified. Approximately five to ten images were cap-
tured per experiment and each experiment was performed
at least three independent times. Statistics were carried
out using Graphpad 6 software.
Rat motor neuron cultures
Mixed spinal cord cultures were prepared from rat and
transfected with virus following previously established
protocols [77, 78]. The titer of herpes simplex virus rou-
tinely used in our studies was 3-5 × 107 plaque forming
units (pfu)/ml [78]. The primary neuron cultures were
infected 14 days in vitro (DIV) with herpes simplex virus
(HSV) expressing either TDP-43 or LacZ. The inhibitor
Veliparib, also called ABT-888 (Selleckchem, # S1004),
or DMSO was added to the cell-culture medium at the
indicated concentration at the time of infection. Media
was changed 3-days post infection and cells were fixed
and processed for immunofluorescence on day 5 of in-
fection. Mouse anti-neurofilament-H, NF-H (1 in 1000,
Biolegend #801703) and mouse AlexaFluor 488 (1 in
500, ThermoFisher, # A-21203) were used to identify
neurons. Five images (10X magnification) were captured
from each condition and remaining neuronal cell bodies
were counted. Each condition was repeated three times,
on three independent cultures. Statistics were performed
in Graphpad 6 software.
Statistics
All data were analyzed in Graphpad Prism 6. To compare
age at death between normal and ALS a Mann-Whitney
Test was used. To compare disease duration between ALS
disease cohorts a Kruskal-Wallis test was used. To com-
pare cytoplasmic or nuclear PAR immunoreactivity be-
tween normal and ALS, or nuclear PAR between ALS and
ALS-D cohorts a Fisher’s exact test was used. To compare
nuclear PAR immunoreactivity between ALS-no mut,
ALS-ATXN2 and ALS-c9, a Chi square (Χ2) test was used.
Cell culture and primary neuron experiments were re-
peated in triplicate and a mean (± SEM) is presented.
One-way or two-way ANOVA followed by the appropriate
post-hoc test was used to test for significance. Details of
statistical tests used are in the associated figure legends.
All experiments were repeated in triplicate unless other-
wise stated. Data were considered statistically significant if
p ≤ 0.05, p values are marked * if p ≤ 0.05, ** if p ≤ 0.01, ***
if p ≤ 0.001 and **** if p ≤ 0.0001.
Results
Study subjects, clinical characteristics and diagnosis
We examined spinal cord tissue from a total of 43 pa-
tients; 16 were negative for any known neurological
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disorder (9 male and 7 female) and are described as the
normal cohort (Fig. 1a and Table 1). As we wanted to
analyze motor neurons and phosphorylated TDP-43 in-
clusions in the ALS spinal cord, we selected cases which
had large alpha neurons that also contained phosphory-
lated TDP-43 inclusions. Of the 27 selected disease cases
(16 male and 11 female), 17 were diagnosed with ALS, 8
with ALS concomitant with dementia (ALS-D), 1 with
ALS concomitant with primary lateral sclerosis (PLS)
and 1 with frontotemporal degeneration (FTD) (Fig. 1b
and Table 2), and are collectively described as the
ALS-cohort. The median age of onset for the disease co-
hort was 59 yr., the median disease duration was 2 yr.
There was no significant difference in the median age at
death between the normal and ALS cohorts (65 yr. vs
62 yr., respectively) (Fig. 1c). Of the ALS cohort, 14 were
negative for known mutations in TARDBP, UBQLN2, FUS,
ATXN2 and C9orf72, 5 had an intermediate polyglutamine
(polyQ) expansion (27–33 CAG repeats) in ATXN2
(ALS-ATXN2), and 8 cases had a G4C2-hexanucleotide
repeat expansion in C9orf72 (ALS-c9) (Table 2). No data
for disease onset was present for two ALS-ATXN2 cases.
No significant difference was detected in this cohort for
disease duration or age at death between ALS-no mut,
ALS-ATXN2 and ALS-c9 (Fig. 1c-d).
Nuclear PAR is elevated in motor neurons of ALS spinal
cord
To ascertain whether PAR activity was misregulated in
disease, we examined the post-mortem spinal cord for
immunoreactivity against PAR. We observed PAR in the
nucleus and cytoplasm of motor neurons in spinal-cord
tissue from both neurologically normal and ALS patients
(Fig. 2a). Tissue sections were coded and blinded and
examined for the presence of PAR in the motor neurons
of the anterior horn. The severity of neuropathological
markers such as phosphorylated TDP-43 are routinely
graded on a semi-quantitative scale [14, 15]. We devel-
oped a semi-quantitative scale to score PAR immunore-
activity in motor neurons (0 not detectable; + detectable
in 1 motor neuron; and ++ detectable in > 1 motor
neuron) and examined staining in both the cytoplasm
and nucleus. Our analysis revealed that 12 out of 14 of
the neurologically normal cases and 27 out of 27 ALS
cases presented with PAR in the cytoplasm of motor
neurons (Fig. 2a-b and Tables 3 and 4). A Fisher’s exact
test revealed no significant difference (p = 0.1329) be-
tween normal and ALS patients, indicating that cyto-
plasmic PAR was not significantly misregulated in this
disease cohort. By contrast, nuclear PAR in the spinal
cord motor neurons was detected in 3 out of 16 normal
cases and in 24 out of 27 ALS cases (Fig. 2a and c, Ta-
bles 3 and 4). All cases that were negative for nuclear
PAR presented with motor neurons with visible nuclei.
A Fisher’s exact test between the normal and ALS cases
revealed that motor neurons with nuclear PAR was sig-
nificantly (p < 0.0001) associated with ALS. Additionally,
the presence of nuclear PAR in the motor neurons of
the spinal cord from ALS-no mut, ALS-ATXN2 and
ALS-c9orf72 did not differ (Χ2 (3) = 0.1436, p = 0.9861)
(Table 4). Given the reported morphological differences
in TDP-43 aggregates in the anterior cingulate of ALS vs
ALS-D patients [106], we compared nuclear PAR in the
motor neurons between these two disease subtypes and
observed no statistical significance (p = 1.0). It is import-
ant to note that the normal anterior horn compared to
Fig. 1 Case demographics. a. Spinal cord tissue from 16 patients with no history of neurodegenerative disease was examined in this study; 7
were female and 9 were male. b. The spinal cord from 27 patients diagnosed with ALS were examined in this study; 11 were female and 16 were
male. c. There was no statistical difference in the age of death between the normal and ALS patients. The graph represents the median with
interquartile range. A Mann-Whitney test was used to test for significance. d. Compared to the no-mutation carriers, the presence of a mutation
in C9orf72 or an intermediate polyQ expansion in ATXN2 did not cause a significant change in disease duration in these pre-selected cohorts. The
graph represents the median with interquartile range. A Kruskal-Wallis test was used to test for significance
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the ALS-all anterior horn had significantly more motor
neurons (19.5±1.4 vs 13.7±1.4 (SEM) p = 0.0081) and
significantly more visible nuclei (5.6±0.6 vs 4.0±0.4
(SEM) p = 0.0393). It is likely that the severity of nuclear
PAR staining in ALS is under represented in our ana-
lyses. Combined, our data indicate that the motor neu-
rons of the post-mortem spinal cord from ALS patients
exhibit significantly elevated levels of nuclear PAR.
Motor neurons do not have cytoplasmic inclusions of PAR
To gain further insight into the pattern of PAR immuno-
reactivity in the ALS spinal cord, we determined
whether PAR formed neuronal cytoplasmic inclusions in
neurons that contained phosphorylated TDP-43. Serial
sections of spinal cord from 4 ALS patients were immu-
nostained with either an antibody that selectively detects
TDP-43 phosphorylated at serines 409/410 (pS409/10)
or with an antibody that detects PAR. In all 4 cases (case
numbers: 22, 23, 25 and 26) cytoplasmic inclusions of
phosphorylated TDP-43 were present in the motor neu-
rons (Fig. 3a). In serial sections, we found no evidence
of PAR aggregation in the cytoplasm in the neurons in
which phosphorylated TDP-43 was detected (Fig. 3a).
Additionally, in these 4 cases (22, 23, 25 and 26) nuclear
Fig. 2 ALS motor neurons have elevated levels of nuclear PAR. a. Spinal cord sections from a neurologically normal case showing a motor
neuron with no nuclear PAR immunoreactivity (arrow). An ALS-no mut case with three motor neurons with nuclear PAR (arrows). An ALS-ATXN2
case with two motor neurons presenting with nuclear PAR (arrows). An ALS-c9 case with one motor neuron with nuclear PAR (arrow). Sections
were immunostained for PAR and counterstained with Hematoxylin. b. The presence of cytoplasmic PAR in the motor neurons of the spinal cord
was quantified on a semi-quantitative scale (0 no detectable cytoplasmic PAR; + cytoplasmic PAR detected in 1 motor neuron; ++ cytoplasmic
PAR detected in > 1 motor neuron), see also Tables 3 and 4. The data was charted as a percentage. c. The presence of nuclear PAR in the motor
neurons of the spinal cord was quantified on a semi-quantitative scale (0 no detectable nuclear PAR; + nuclear PAR detected in 1 motor neuron;
++ nuclear PAR detected in > 1 motor neuron), see also Tables 3 and 4. The data were charted as a percentage. Slides were fully blinded and
examined independently by two researchers, images for figures were captured with a 20X objective and an optivar magnification of 1.6
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PAR was present in motor neurons, and in serial sec-
tions none of those motor neurons displayed phosphory-
lated TDP-43 pathology (Fig. 3b). These data indicate
that nuclear PAR occurred in motor neurons that have
not developed phosphorylated TDP-43 pathology.
Veliparib suppresses the formation of stress-induced foci
of TDP-43
Since nuclear PAR was detected in motor neurons of the
ALS spinal cord, the activity of the nuclear PARPs may
be activated in disease. There are three nuclear PARP
enzymes: PARP-1, PARP-2, and also PARP-3, which is a
mono(ADP-ribose) transferase [41, 48, 60]. The antibody
used to detect PAR recognizes PAR chains of 20 or more
ADP-ribose subunits [52], suggesting that the PAR de-
tected in the ALS spinal cord (see Figs. 2 and 3) is gen-
erated from PARP-1 or PARP-2 (collectively known as
PARP-1/2). Small-molecule inhibitors of PARP-1/2 activ-
ity have been pursued as cancer therapeutics in more
than 300 FDA-approved clinical trials [54, 102]. We thus
sought to determine if PARP-1/2 inhibition could be of
potential therapeutic value to ALS.
In cells, TDP-43 can be induced to aggregate and
localize to cytoplasmic stress granules. It has been re-
ported that the PARP-1/2 inhibitor, Veliparib, inhibits
the formation cytoplasmic stress granules [23, 49]. We
determined the efficacy of Veliparib to mitigate the for-
mation of arsenite-induced TIAR-labelled stress granules
in COS-7 cells (Fig. 4a). Upon exposure to 0.25 mM
sodium arsenite, the percentage of cells with TIAR-la-
belled stress granules increased from 6±1% to 29±2%
(SEM) (Fig. 4b-c). Co-treatment with 10 μM Veliparib
reduced the percentage of cells with arsenite-induced
TIAR-labelled stress granules to 9±1% (SEM) (Fig. 4b-c).
To examine the efficacy of Veliparib to mitigate cytoplas-
mic aggregation of TDP-43 in COS-7 cells, we exogen-
ously expressed TDP-43-YFP. Normally, TDP-43-YFP was
diffusely nuclear, however upon exposure to 0.25 mM so-
dium arsenite the percentage of cells with cytoplasmic
TDP-43-YFP foci increased from 3±1% to 30±1% (SEM)
(Fig. 4d-e). Co-treatment with Veliparib significantly re-
duced the percentage of cells with arsenite-induced
TDP-43-YFP foci to near control levels (5±1% (SEM))
(Fig. 4d-e). These data suggest that in response to arsenite
exposure, PARP-1/2 activity regulates stress-granule for-
mation and stress-induced TDP-43 aggregation in the
cytoplasm.
Veliparib mitigates TDP-43 toxicity in primary spinal cord
neurons
Since Veliparib inhibited the accumulation of stress-in-
duced TDP-43 foci in the cytoplasm, we queried
whether this treatment could impact the toxicity of
TDP-43 to primary spinal cord cultures. To address this
question, we developed a toxicity assay in mixed
spinal-cord cultures isolated from rat embryos (Fig. 5a).
The primary spinal cord cultures were virally infected
with an attenuated herpes simplex virus expressing a
LacZ control or of TDP-43. The cultures were main-
tained for 5d post infection, after which they were im-
munostained for the neuronal specific marker
Neurofilament-H (NF-H) and the remaining
NF-H-labeled cell bodies were imaged and quantified. In
control conditions (LacZ), we observed an average of
102±5.6 (SEM) neuronal cell bodies (Fig. 5b-c). Infection
with TDP-43 at 0.25×, 0.5× and 1× resulted in a
dose-sensitive loss of neurons (76±2.2, 63±2.4 and 38
±2.4 (SEM) neuronal cell bodies respectively) (Fig. 5b-c),
indicating that virally expressed TDP-43 results in neur-
onal cell loss in rat spinal cord cultures.
To determine if Veliparib was effective at mitigating
TDP-43-associated neuronal degeneration, we first ex-
amined spinal cord cultures infected with the LacZ con-
trol and treated with either DMSO or with 1 μM or
5 μM Veliparib. These controls revealed that Veliparib
had no deleterious effects on the mixed spinal cord cul-
tures at the concentrations tested (Fig. 5b-c). We then
compared rat spinal cord cultures infected with TDP-43
and co-treated with DMSO or 1 μM or 5 μM Veliparib.
Notably, treatment with 5 μM Veliparib protected the
primary neurons such that there was no significant dif-
ference in the number of neuronal cell bodies, at all in-
fection ratios of TDP-43 compared to the DMSO
Table 3 PAR immunoreactivity in patients with no known
neurological disease
# Diagnosis Region
analyzed
PAR in
MN nuclei
PAR in MN
cytoplasm
1 normal cervical 0 0
2 normal cervical 0 ++
3 normal cervical ++ ++
4 normal cervical 0 ++
5 normal cervical 0 0
6 normal cervical 0 ++
7 normal lumbar + +
8 normal cervical 0 +
9 normal lumbar 0 ++
10 normal cervical 0 ++
11 normal cervical 0 ++
12 normal cervical 0 ++
13 normal cervical ++ ++
14 normal thoracic 0 ++
15 normal cervical 0 ++
16 normal cervical 0 ++
Abbreviations: #: case number. Normal diagnosed neurologically normal. F
female, M, male. PAR poly(ADP-ribose). MN motor neuron
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Fig. 3 PAR does not form protein aggregates in the cytoplasm of motor neurons. a. Serial sections from ALS spinal cord tissue were stained
for either PAR or phosphorylated TDP-43 (pS409/10). Motor neurons with phosphorylated TDP-43 aggregates did not also have cytoplasmic
aggregates labelled with PAR. Arrowheads indicate the same neurons in each serial section. Scale bar: 50 μm. b. Serial sections of ALS spinal cord
tissue were stained for either PAR or phosphorylated TDP-43 (pS409/10). The motor neurons shown with elevated nuclear PAR did not have
cytoplasmic aggregates of phosphorylated TDP-43. Arrowheads indicate the same neuron in each section. Arrows indicate neuron with nuclear
PAR. Scale bar: 50 μm
Table 4 PAR immunoreactivity in patients diagnosed with neurological disease
# Diagnosis Mutation Status Region analyzed PAR in MN nuclei PAR in MN cytoplasm
17 ALS – cervical + ++
18 ALS – lumbar ++ ++
19 ALS – cervical ++ ++
20 ALS-D – lumbar ++ ++
21 ALS – lumbar ++ ++
22 ALS – lumbar ++ ++
23 ALS – lumbar 0 ++
24 ALS – cervical + ++
25 ALS – cervical + ++
26 ALS-D – cervical ++ ++
27 ALS/PLS – cervical + ++
28 ALS – cervical 0 ++
29 ALS – lumbar ++ ++
30 ALS – cervical + ++
31 ALS ATXN2 (22/32) cervical ++ ++
32 ALS-D ATXN2 (22/27) cervical ++ ++
33 ALS ATXN2 (20/31) thoracic ++ ++
34 ALS ATXN2 (22/29) lumbar ++ ++
35 ALS ATXN2 (22/27) cervical 0 ++
36 ALS C9orf72 cervical ++ ++
37 FTD C9orf72 cervical ++ ++
38 ALS-D C9orf72 cervical ++ ++
39 ALS-D C9orf72 thoracic 0 ++
40 ALS-D C9orf72 thoracic ++ ++
41 ALS-D C9orf72 cervical + ++
42 ALS-D C9orf72 lumbar ++ ++
43 ALS C9orf72 sacral + ++
Abbreviations: #: case number. -: No known mutation in TARDBP, UBQLN2, ATXN2, and C9orf72. ATXN2 refers to an intermediate CAG-trinucleotide expansion in
ATXN2 (pathologic repeat length is indicated in brackets). C9orf72 refers to a GGGGCC-hexanucleotide repeat expansion. ALS-D ALS with dementia, FTD
frontotemporal degeneration, PLS primary lateral sclerosis, PAR poly(ADP-ribose), MN motor neuron
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control (Fig. 5b-c). The neuronal processes appeared
retained although not to the level of the control (Fig.
5c). These studies cannot determine whether the neu-
rons or astrocytes account for TDP-43-associated neur-
onal loss or for the beneficial action of Veliparib.
However, small molecule inhibition of PARP-1/2 is ef-
fective in mitigating TDP-43-associated neuronal loss in
these spinal cord cultures, and could have therapeutic
utility for ALS and other TDP-43-associated diseases.
Discussion
Our data indicate that ALS is associated with elevated
nuclear PAR in the motor neurons of the spinal cord in
all genetic backgrounds tested (no mutation, intermedi-
ate polyQ expansion in ATXN2 or C9orf72 mutation).
We show that Veliparib, an inhibitor of nuclear PARP-1/
2 activity, mitigates the formation of stress-induced cyto-
plasmic aggregates of TDP-43 in mammalian cells. We
extend this finding to show that treating rodent
spinal-cord cultures with Veliparib mitigates
TDP-43-induced neuronal cell loss. Collectively, our
data implicate the misregulation of nuclear PARP activ-
ity in ALS and highlight PARP-1/2 inhibitors as potential
compounds for further therapeutic research.
In the early stages of ALS some patients will present
with symptoms of neuronal hyperexcitability such as fas-
ciculation and cramp [7, 111]. In support of hyperexcit-
ability as a physiological mechanism, glutamate, the
major excitatory neurotransmitter in the CNS, is ele-
vated in the cerebrospinal fluid of ALS patients [93, 94,
101, 103]. Notably, PARP-1 activation has been impli-
cated in meditating the response to glutamate-induced
neurotoxicity in animal and cellular assays [5, 24, 113,
116]. Our neuropathologic analyses demonstrate that
long-chained PAR polymers are present at elevated levels
in the motor-neuron nuclei of the ALS spinal cord. This
Fig. 4 Small molecule inhibition of PARP-1/2 reduces the formation of stress-induced TDP-43 foci in mammalian cells. a Veliparib is a small molecule
inhibitor of PARP-1/2 activity reported to inhibit the formation of G3BP1-labelled foci in the cytoplasm upon UV treatment [49]. b Exposure to arsenite
leads to the formation of TIAR-labelled stress granules in the cytoplasm (arrows). Co-treatment with Veliparib inhibits the formation of TIAR-labelled
stress granules. COS-7 cells transfected with TDP-43-YFP were immunostained for TIAR and counterstained with Hoescht. Cells were imaged for TIAR
and Hoescht. c Cells were quantified for the presence of cytoplasmic TIAR-labelled stress granules. Mean (± SEM) is presented. One-way
ANOVA followed by a Tukey’s test was used for significance. d Under normal conditions (ctrl), TDP-43-YFP diffusely localizes to the nucleus of
COS-7 cells. Upon treatment with arsenite, TDP-43-YFP forms foci in the cytoplasm (arrows). The formation of cytoplasmic TDP-43-YFP foci is
inhibited by treatment with Veliparib. Cells were counterstained with Hoescht. e Veliparib reduces the accumulation of TDP-43-YFP foci in the
cytoplasm. Cells were quantified for the presence of cytoplasmic TDP-43-YFP foci. Mean (± SEM) is presented. One-way ANOVA (p = 0.0002)
followed by a Tukey’s test was used for significance. f Hypothetical schematic showing that inhibition of PARP-1/2 activation by Veliparib
inhibits the formation of stress-induced TDP-43-YFP foci
McGurk et al. Acta Neuropathologica Communications  (2018) 6:84 Page 9 of 15
finding implicates activation of the nuclear PARP en-
zymes (PARP-1 and PARP-2). PARP-1 is the most abun-
dant and the most active following stress [27, 67]. The
downstream consequence of PARP-1 activation leads to
the propagation of several stress-associated pathways [1,
21, 34, 63]. Upon over activation of PARP-1, the enzyme
elicits a cell death mechanism, which is characterized by
cleavage of PARP-1 [34, 50, 100]. Previous reports indi-
cate that PARP-1 protein and cleaved PARP-1 is elevated
in ALS [32, 56, 57]. Combined with our data that dem-
onstrate that PAR is elevated in ALS motor neurons it
could be that PARP-1/2 is activated by localized glutam-
ate excitotoxicity and that the motor neurons may be
undergoing PAR-mediated cell death.
PARP-1/2 also plays a role in nuclear and cytoplasmic
protein localization. For example, upon inflammatory
stress, PARP-1/2 promotes nuclear retention of the tran-
scription factor High mobility group B1 (HMGBP1) [1].
Under extreme conditions of DNA damage PAR polymers
produced by PARP-1 are released into the cytoplasm and
bind to Apoptosis Inducing Factor (AIF) in the mitochon-
dria to promote translocation of AIF and macrophage mi-
gration inhibitory factor (MIF) to the nucleus to elicit a
programmed cell death mechanism [34, 113, 114].
PARP-1 activity has also been implicated in signaling to
PARP-12 in the cytoplasm to regulate the formation of
cytoplasmic stress granules [23, 49]. Here we show that
treatment with PARP-1/2 inhibitor, Veliparib, mitigates
Fig. 5 Veliparib inhibits TDP-43-associated neuronal loss in rat spinal cord cultures. a. The spinal cord was isolated from Sprague Dawley embryos
(E16-E18), dissociated with protease and DNase, and seeded onto astrocyte coated 12-well plates. After 1 day in vitro (1 DIV) cell proliferation was
stopped by the addition of 5 μM cytosine arabinoside (AraC). At 14 DIV cultures were infected with a LacZ control or TDP-43 attenuated herpes
simplex virus alongside DMSO or Veliparib. At 19 DIV the neurons were fixed and immunostained for the neuronal marker neurofilament-H (NF-H)
and counterstained with Hoescht. Five images (10X magnification) were captured from each condition and neuronal cell bodies were counted.
Each condition was repeated three times from 3 independent cultures. b. Viral infection of TDP-43 leads to the loss of neuronal cell bodies in
dose-dependent manner. Co-treatment with 1 μM or 5 μM Veliparib inhibits TDP-43-induced neuronal cell loss. Mean (± SEM) is presented, each
data point represents three technical repeats from an independent culture. 1X represents a virus titer of 3-5 × 104 pfu/ml. Two-way ANOVA (p < 0.0001)
and a Dunnett’s test for significance was performed. NS: not significant. c. Example images (magnification 10X), of rat spinal-cord cultures infected with
1X LacZ or 1X TDP-43 and incubated with DMSO or 5 μM Veliparib. Cultures were immunolabeled for Neuro filament-H (NF-H) and counterstained with
Hoescht. d. Schematic showing that motor neuron loss induced by virally expressed TDP-43 in spinal cord cultures and that this loss is suppressed by the
PARP-1/2 inhibitor Veliparib
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the formation of stress-induced aggregates of TDP-43 in the
cytoplasm, suggesting that PARP-1/2 activity impacts cyto-
plasmic aggregation of TDP-43. Indeed, nuclear PAR was
not detected in neurons harboring phosphorylated TDP-43
aggregates, suggesting that the PARP-1/2 activation ob-
served in ALS motor neurons may occur at earlier stages in
neuron compromise. We suggest that PARP-1/2 activation
may precede the exit of TDP-43 from the nucleus and the
subsequent formation of cytoplasmic TDP-43 aggregates.
Of the ~ 5% of ALS cases that lack TDP-43 pathology
(TDP-43-negative ALS), a subset is the result of a muta-
tion in FUS (fused in sarcoma) [46, 61, 112]. FUS is an
RNA-binding protein that is recruited to sites of DNA
damage by PARP-1 [3, 81, 96] and at high concentrations,
the PARP-1/2 inhibitor Veliparib can promote the mislo-
calization of nuclear FUS-GFP to the cytoplasm [81]. A
second notable gene mutated in TDP-43-negative ALS is
SOD1 (superoxide dismutase 1) [69]. Curiously, PARP-1
protein is elevated in spinal cord astrocytes in SOD1
G93A transgenic mice [22] and is cleaved in SOD-1 cellu-
lar models [59]. However, pharmacological treatment with
a PARP-1 inhibitor had no effect on the lifespan or motor
performance of the SOD1 G93A transgenic mouse [6]. It
is possible that PARP-1/2 regulation of neuronal demise is
selectively involved in TDP-43-positive ALS. In support
of PARP-1 mediated regulation of the central nervous
system in disease it has been shown that PARP-1 over-
activation leads to neuronal degeneration in Drosophila
[43]. PARP-1 activation has also been linked to Alzhei-
mer’s (AD), Parkinson’s (PD) and ischemic stroke [19,
31, 51, 71, 72, 79], and the use of PARP-1/2 inhibitors
is beneficial to mouse models of these diseases [2, 20,
25, 30, 87, 105, 109, 115]. These data indicate that, des-
pite dampening the DNA damage response, PARP-1/2
inhibition provides improved neuronal integrity and func-
tion in these animal models of disease. To assign thera-
peutic potential of PARP-1/2 inhibitors and understand
potential side effects, it will be imperative to examine add-
itional ALS subtypes and associated diseases.
A range of small-molecule inhibitors of PARP-1/2, in-
cluding the inhibitor used here, have been developed for
clinical application as they sensitize cancer cells to cell
death. Moreover, some have been reported to cross the
blood-brain barrier [16, 17, 33]. These inhibitors have
been tested in hundreds of FDA-approved clinical trials of
various cancers and there is a wealth of information on
the pharmacokinetics, pharmacodynamics, and toxicity of
these compounds that would be beneficial in repurposing
them for alternative diseases [11, 54, 102]. We previously
implicated inhibitors of PARP-5a and PARP-5b, collect-
ively known as PARP-5a/5b, in reducing the cytoplasmic
aggregation of TDP-43, without having an effect on the
percentage of cells with G3BP1-positive stress granules
[73]. PARP-5a/5b inhibitors are also in development as
cancer therapeutics [42, 62, 70]. It is possible that
PARP-1/2 more broadly effects stress granule formation
and stress-induced protein aggregation, while PARP-5a/5b
may act on select proteins in stress signaling.
Conclusion
Our study implicates the activation of PARP-1/2 in the
motor neuron nuclei of the ALS spinal cord. We show
that treatment with Veliparib, a PARP-1/2 inhibitor, re-
duces stress-induced accumulation of TDP-43 in the
cytoplasm of mammalian cells. Furthermore, we show
that Veliparib can mitigate the toxic effect of virally
expressed TDP-43 in rodent spinal cord cultures. Cur-
rently, the mechanisms that may link TDP-43 and
PARP-1/2 in cell culture models and human disease re-
mains to be elucidated. We suggest that the PARP super-
family is an area that should be explored further in ALS
therapeutics.
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